Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway

詳細情報 詳細情報について

• CRID

  1360574094773488512

• DOI

  10.3389/fphar.2018.01214

• ISSN

  16639812

• Web Site

  https://www.frontiersin.org/article/10.3389/fphar.2018.01214/full

• データソース種別

  • Crossref